Aod-9604 peptide

AOD-9604 was designed to replicate growth hormone's fat-burning capacity without triggering its insulin resistance or tissue-growth effects. What emerged from the clinical trials was something stranger: evidence of cartilage repair that has nothing to do with lipolysis, and no clear mechanism to explain how a non-receptor-binding fragment could affect either.

A 16-Amino-Acid Fragment That Was Never Supposed to Bind Anything

AOD-9604 is a synthetic peptide containing amino acids 177–191 from the C-terminal region of human growth hormone (hGH), with an additional tyrosine residue added to the N-terminus for stability. The molecular weight is 1815.08 Da. Researchers at Monash University in Australia isolated this fragment after discovering that the lipolytic activity of growth hormone could be separated from its growth-promoting effects by focusing on the tail end of the molecule.

Unlike full-length hGH, which binds to the growth hormone receptor and activates the JAK2-STAT5 pathway to stimulate IGF-1 production, AOD-9604 does not appear to bind the GHR at all. Receptor binding assays have failed to demonstrate meaningful affinity. This structural modification was deliberate: the aim was to avoid the insulin resistance and soft-tissue growth that make prolonged growth hormone therapy problematic in non-deficient adults.

The compound reached Phase II clinical trials for obesity in the early 2000s but was not approved by any major regulatory authority. It remains classified as a research compound and is intended for research purposes only.

How a Non-Receptor Peptide Might Still Activate Lipolysis

The mechanism by which AOD-9604 promotes fat breakdown remains speculative. The most cited hypothesis is that it stimulates beta-3 adrenergic receptors on adipocytes, which activates hormone-sensitive lipase (HSL) and increases free fatty acid release. This pathway is independent of the growth hormone receptor and does not require IGF-1 induction. Cell culture studies in murine 3T3-L1 adipocytes showed increased lipolysis after AOD-9604 treatment, with effects comparable to isoproterenol, a known beta-adrenergic agonist.

Other proposed mechanisms include direct interaction with lipid-regulating enzymes or modulation of AMP-activated protein kinase (AMPK), though evidence is thin. Notably, in vivo studies in obese Zucker rats and diet-induced obese mice demonstrated dose-dependent reductions in body fat without changes in lean mass or food intake. The effect appeared selective to visceral adipose tissue, with minimal impact on subcutaneous depots in some rodent models.

The cartilage repair activity—discovered incidentally—appears to involve transforming growth factor-beta (TGF-β) signaling. In vitro studies using human osteoarthritic chondrocytes showed increased proteoglycan synthesis and collagen II expression after AOD-9604 treatment. The compound enhanced TGF-β receptor expression and downstream Smad2/3 phosphorylation, suggesting a pro-anabolic effect on cartilage matrix. This mechanism is entirely separate from its lipolytic action and raises the question of whether the peptide has multiple binding sites or whether indirect signaling is involved.

What the Clinical and Preclinical Data Actually Show

The lipolytic effects of AOD-9604 were first demonstrated in vitro using rat and mouse adipocytes. Treated cells showed a 2- to 3-fold increase in glycerol release compared to controls, with the effect blocked by beta-adrenergic antagonists. In Zucker rats—a genetic model of obesity—subcutaneous injections of 500 µg/kg daily for 13 days reduced body fat by approximately 50% compared to saline controls, with no change in lean tissue mass or blood glucose.

In diet-induced obese mice, AOD-9604 at doses between 125 and 500 µg/kg reduced body weight gain and visceral fat accumulation over 18 weeks. The compound did not alter food intake or locomotor activity, suggesting a metabolic rather than appetite-driven mechanism. Importantly, treated animals did not show the elevated IGF-1 levels or insulin resistance typical of growth hormone administration.

Human data are limited to two Phase II trials. The first was a 12-week randomized, placebo-controlled study in 300 obese adults. Subjects received subcutaneous AOD-9604 at doses ranging from 1 mg to 10 mg daily. The primary outcome—change in body weight—showed modest reductions in the treatment groups, but the differences did not reach statistical significance for most dose levels. A secondary analysis suggested greater fat loss in the trunk region, measured by DEXA, though the effect size was small.

The second trial, conducted in Australia, enrolled 500 participants for 12 weeks with similar dose ranges. Results were never published in full, and the sponsoring company, Metabolic Pharmaceuticals, did not pursue regulatory approval after consultations with the FDA and Australian TGA. Safety monitoring showed no serious adverse events directly attributable to the peptide, but the lack of efficacy at the primary endpoint ended its development as an obesity drug.

The cartilage repair data come from a small body of preclinical work. In a rabbit anterior cruciate ligament transection model—an established model of post-traumatic osteoarthritis—intra-articular injections of AOD-9604 twice weekly for 4 weeks reduced cartilage degradation markers and improved histological scores compared to saline. Treated joints showed thicker cartilage with more organized collagen structure. A follow-up study in a rat osteochondral defect model showed enhanced proteoglycan deposition and partial defect filling at 8 weeks.

No human trials have tested AOD-9604 specifically for cartilage repair, though a single case series mentioned off-label use in five patients with knee osteoarthritis who reported subjective pain improvement. The report lacked controls, objective imaging, or biochemical markers, making it impossible to draw conclusions.

Dosing, Stability, and Administration in Research Contexts

Published preclinical studies used subcutaneous doses between 125 and 500 µg/kg in rodents, typically administered once daily. Extrapolating to a 70 kg human using allometric scaling suggests a rough equivalence of 10–40 mg daily, which aligns with the doses tested in clinical trials. Intra-articular dosing in rabbit models ranged from 500 µg to 1 mg per joint, delivered twice weekly.

The peptide has a short plasma half-life, estimated at less than 1 hour in rats following subcutaneous injection. Peak plasma concentrations occurred within 30 minutes. This pharmacokinetic profile suggests the need for frequent dosing or sustained-release formulations to maintain tissue exposure, though most rodent studies achieved effects with once-daily administration.

AOD-9604 is supplied as a lyophilized powder and is typically reconstituted with bacteriostatic water for injection. Once reconstituted, the peptide remains stable for several weeks when refrigerated at 2–8°C, though some researchers recommend freezing aliquots to minimize degradation. The peptide is sensitive to repeated freeze-thaw cycles, which can lead to aggregation and loss of activity.

There are no published drug interaction studies. Given its independence from the growth hormone receptor, AOD-9604 is unlikely to potentiate or interfere with exogenous hGH or IGF-1 analogs. However, co-administration with beta-adrenergic agonists (e.g., clenbuterol) could theoretically amplify lipolytic signaling, though this has not been tested formally.

FAQ

Q: Does AOD-9604 increase growth hormone or IGF-1 levels?

No. Unlike full-length hGH, AOD-9604 does not bind to the growth hormone receptor and does not stimulate hepatic IGF-1 production. In both rodent studies and human trials, circulating IGF-1 levels remained unchanged following AOD-9604 administration. This is one of the defining features that distinguishes it from intact growth hormone.

Q: Why did the obesity trials fail despite positive rodent data?

The most likely explanation is species-specific differences in adipocyte biology and beta-adrenergic receptor density. Rodent adipose tissue is more responsive to lipolytic stimuli than human fat, and the doses that worked in mice may not have achieved sufficient receptor occupancy in humans. The clinical trials also faced issues with compliance and heterogeneous baseline metabolic profiles, which diluted the treatment effect.

Q: Is there any human evidence for the cartilage repair effects?

No controlled human data exist. The only mention in the literature is an anecdotal case series with five patients, none of whom underwent imaging or biochemical assessment. All cartilage repair evidence comes from in vitro chondrocyte studies and small animal models of joint injury. Human cartilage trials would require intra-articular administration and multi-month follow-up with MRI or arthroscopy.

Q: Can AOD-9604 be detected in standard anti-doping tests?

The peptide's short half-life and small size make it difficult to detect using conventional immunoassays. However, high-resolution mass spectrometry methods can identify synthetic peptide fragments in urine or plasma for a limited window post-administration. The World Anti-Doping Agency (WADA) classifies growth hormone fragments under prohibited substances, and AOD-9604 falls within that category despite its lack of receptor binding.

Q: What remains unknown about the mechanism?

The largest gap is explaining how a peptide that does not bind the growth hormone receptor produces any biological effect at all. The beta-adrenergic hypothesis is plausible but unproven in humans. The cartilage repair pathway involving TGF-β is even less understood—there is no obvious binding site or receptor candidate. It is possible that the fragment acts as an allosteric modulator or that it undergoes post-translational modification in vivo that changes its activity.

---

This article is for informational and educational purposes only and is not intended as medical advice. AOD-9604 is not approved for clinical use and should not be used outside of formal research settings under appropriate ethical oversight.